STOCK TITAN
  1. Home
  2. News
  3. ASND

Ascendis Pharma A/S - ASND STOCK NEWS

IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
clinical trial
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma Reports Second Quarter 2023 Financial Results
earnings
IMPACT
SENTIMENT
ASND : Nasdaq
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
IMPACT
SENTIMENT
ASND : Nasdaq
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
conferences
IMPACT
SENTIMENT
ASND : OTC ASDRF : OTC ASND : OTC
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders
Stock ASND logo
Ascendis Pharma A/S
Nasdaq:ASND

ASND Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About ASND

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.